Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALLO
stocks logo

ALLO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.223
-20.28%
--
--
-0.220
-21.43%
--
--
-0.232
+4.45%
Estimates Revision
The market is revising Downward the revenue expectations for Allogene Therapeutics, Inc. (ALLO) for FY2025, with the revenue forecasts being adjusted by -45.78% over the past three months. During the same period, the stock price has changed by 25.22%.
Revenue Estimates for FY2025
Revise Downward
down Image
-45.78%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-7.83%
In Past 3 Month
Stock Price
Go Up
up Image
+25.22%
In Past 3 Month
Wall Street analysts forecast ALLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLO is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast ALLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLO is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
1 Sell
Strong Buy
Current: 1.440
sliders
Low
7.00
Averages
9.17
High
14.00
Current: 1.440
sliders
Low
7.00
Averages
9.17
High
14.00
Oppenheimer
Oppenheimer
Outperform
to
Outperform
downgrade
$9 -> $7
2025-08-01
Reason
Oppenheimer
Oppenheimer
Price Target
$9 -> $7
2025-08-01
downgrade
Outperform
to
Outperform
Reason
Oppenheimer lowered the firm's price target on Allogene Therapeutics to $7 from $9 and keeps an Outperform rating on the shares. The company closed the ALLO-647 arm of the Phase 2 ALPHA3 study and will not pursue further trials with it after a death, the analyst tells investors in a research note. The firm is more concerned about the death's impact on trial enrollment than it is about the ramifications of removing ALLO-647 might have on efficacy. However, it still thinks ALPHA3 "is a worthy endeavor that has the potential to be paradigm-changing."
JPMorgan
Brian Cheng
Overweight -> Neutral
downgrade
2025-08-01
Reason
JPMorgan
Brian Cheng
Price Target
2025-08-01
downgrade
Overweight -> Neutral
Reason
JPMorgan analyst Brian Cheng downgraded Allogene Therapeutics to Neutral from Overweight with no price target after the company reported a fatal event in cemacabtagene ansegedleucel, or cema-cel's, pivotal front-line consolidation large B-cell lymphoma ALPHA 3 study. The announcement "came as a surprise," says the analyst, who finds it "difficult to remain confident in cema-cel" following a recent series of setbacks. After updating the firm's model to reflect today's announcement, the firm is lowering penetration assumptions and probability of success for cema-cel in first-line consolidation LBCL, the analyst noted.
Citizens JMP
Outperform -> Market Perform
downgrade
2025-05-14
Reason
Citizens JMP
Price Target
2025-05-14
downgrade
Outperform -> Market Perform
Reason
Citizens JMP downgraded Allogene Therapeutics to Market Perform from Outperform without a price target post the Q1 report. The firm cites a lack of near-term milestones and longer than expected ALPHA3 development timelines for the downgrade. The firm removed the ALLO-501A revenues from its model, which was the lead program driving its valuation methodology for the shares.
Piper Sandler
Overweight
maintain
$9 -> $7
2025-05-14
Reason
Piper Sandler
Price Target
$9 -> $7
2025-05-14
maintain
Overweight
Reason
Piper Sandler lowered the firm's price target on Allogene Therapeutics to $7 from $9 and keeps an Overweight rating on the shares. The firm notes the company reported its Q1 2025 earnings where the next data update from the ALPHA3 trial of cema-cel in the first line consolidation setting has been pushed to the first half of 2026 from mid-2025. Main reasons for the delay include inadequate staffing at sites and patient retention for initial MRD testing.
Baird
Jack Allen
Outperform
downgrade
$12 -> $9
2025-05-14
Reason
Baird
Jack Allen
Price Target
$12 -> $9
2025-05-14
downgrade
Outperform
Reason
Baird analyst Jack Allen lowered the firm's price target on Allogene Therapeutics to $9 from $12 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its ALPHA3 Lymphodepletion decision and ALLO-329 data was pushed to 1H26.
Oppenheimer
Oppenheimer
Outperform
maintain
$10 -> $9
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$10 -> $9
2025-05-14
maintain
Outperform
Reason
Oppenheimer lowered the firm's price target on Allogene Therapeutics to $9 from $10 and keeps an Outperform rating on the shares following quarterly results. The most notable update was that ALPHA3's first update is being pushed back 6 months. Management said that sites were taking longer to recruit patients than anticipated-and they took full responsibility for it, the firm says.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Allogene Therapeutics Inc (ALLO.O) is -1.58, compared to its 5-year average forward P/E of -4.48. For a more detailed relative valuation and DCF analysis to assess Allogene Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-4.48
Current PE
-1.58
Overvalued PE
-0.19
Undervalued PE
-8.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.79
Undervalued EV/EBITDA
-7.33

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
29013.17
Current PS
0.00
Overvalued PS
106973.79
Undervalued PS
-48947.46
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 241.06% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 241.06% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ALLO News & Events

Events Timeline

(ET)
2025-11-06
17:52:40
Allogene Therapeutics announces Q3 earnings per share of 19 cents, below consensus estimate of 23 cents.
select
2025-08-13 (ET)
2025-08-13
16:12:16
Allogene Therapeutics reports Q2 EPS (23c), consensus (27c)
select
2025-08-01 (ET)
2025-08-01
08:36:35
Allogene Therapeutics selects lymphodepletion regimen for ALPHA3 study
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
10-10NASDAQ.COM
CDTX Shares Rise Following FDA's Breakthrough Therapy Designation for CD388 in Influenza

  • FDA Breakthrough Therapy Designation: Cidara Therapeutics received FDA Breakthrough Therapy designation for its candidate CD388, aimed at preventing seasonal influenza, leading to a 12.4% increase in the company's shares.

  • CD388's Mechanism and Efficacy: CD388 is a long-acting small molecule inhibitor that offers broad protection against seasonal and pandemic flu strains, requiring only a single injection for an entire flu season, independent of the body's immune response.

[object Object]
Preview
4.0
10-10Benzinga
Keysight Analyst Changes Stance; Check Out the Top 5 Downgrades for Friday

  • Analyst Downgrades: Several top Wall Street analysts have downgraded their ratings on various stocks, including Akero Therapeutics, HSBC Holdings, Doximity, Keysight Technologies, and Allogene Therapeutics.

  • Price Target Adjustments: Analysts have also adjusted price targets for these companies, with notable changes such as Akero's target reduced from $72 to $54 and Doximity's target set at $62.

[object Object]
Preview
4.0
10-10Benzinga
JP Morgan Lowers Allogene Therapeutics Rating to Underweight

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, benefiting from exclusive stories and accurate market intelligence.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Allogene Therapeutics Inc (ALLO) stock price today?

The current price of ALLO is 1.44 USD — it has decreased -5.26 % in the last trading day.

arrow icon

What is Allogene Therapeutics Inc (ALLO)'s business?

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

arrow icon

What is the price predicton of ALLO Stock?

Wall Street analysts forecast ALLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALLO is 9.17 USD with a low forecast of 7.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Allogene Therapeutics Inc (ALLO)'s revenue for the last quarter?

Allogene Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Allogene Therapeutics Inc (ALLO)'s earnings per share (EPS) for the last quarter?

Allogene Therapeutics Inc. EPS for the last quarter amounts to -0.19 USD, decreased -40.62 % YoY.

arrow icon

What changes have occurred in the market's expectations for Allogene Therapeutics Inc (ALLO)'s fundamentals?

The market is revising Downward the revenue expectations for Allogene Therapeutics, Inc. (ALLO) for FY2025, with the revenue forecasts being adjusted by -45.78% over the past three months. During the same period, the stock price has changed by 25.22%.
arrow icon

How many employees does Allogene Therapeutics Inc (ALLO). have?

Allogene Therapeutics Inc (ALLO) has 226 emplpoyees as of December 05 2025.

arrow icon

What is Allogene Therapeutics Inc (ALLO) market cap?

Today ALLO has the market capitalization of 323.61M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free